These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25285886)

  • 1. Efficacy of Type 2 PRRSV vaccine against Chinese and Vietnamese HP-PRRSV challenge in pigs.
    Lager KM; Schlink SN; Brockmeier SL; Miller LC; Henningson JN; Kappes MA; Kehrli ME; Loving CL; Guo B; Swenson SL; Yang HC; Faaberg KS
    Vaccine; 2014 Nov; 32(48):6457-62. PubMed ID: 25285886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two genetically distant type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against Vietnamese highly pathogenic PRRSV.
    Do DT; Park C; Choi K; Jeong J; Nguyen TT; Nguyen KD; Vo DT; Chae C
    Vet Microbiol; 2015 Sep; 179(3-4):233-41. PubMed ID: 26149103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pigs immunized with Chinese highly pathogenic PRRS virus modified live vaccine are protected from challenge with North American PRRSV strain NADC-20.
    Galliher-Beckley A; Li X; Bates JT; Madera R; Waters A; Nietfeld J; Henningson J; He D; Feng W; Chen R; Shi J
    Vaccine; 2015 Jul; 33(30):3518-25. PubMed ID: 26049004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a modified-live virus vaccine in pigs experimentally infected with a highly pathogenic porcine reproductive and respiratory syndrome virus type 1 (HP-PRRSV-1).
    Canelli E; Catella A; Borghetti P; Ferrari L; Ogno G; De Angelis E; Bonilauri P; Guazzetti S; Nardini R; Martelli P
    Vet Microbiol; 2018 Nov; 226():89-96. PubMed ID: 30389048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity.
    Martelli P; Gozio S; Ferrari L; Rosina S; De Angelis E; Quintavalla C; Bottarelli E; Borghetti P
    Vaccine; 2009 Jun; 27(28):3788-99. PubMed ID: 19442420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of live attenuated porcine reproductive and respiratory syndrome virus 2 strains to protect pigs from challenge with a heterologous Vietnamese PRRSV 2 field strain.
    Sattler T; Pikalo J; Wodak E; Revilla-Fernández S; Steinrigl A; Bagó Z; Entenfellner F; Claude JB; Pez F; Francillette M; Schmoll F
    BMC Vet Res; 2018 Apr; 14(1):133. PubMed ID: 29673363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response and protective efficacy of intramuscular and intradermal vaccination with porcine reproductive and respiratory syndrome virus 1 (PRRSV-1) modified live vaccine against highly pathogenic PRRSV-2 (HP-PRRSV-2) challenge, either alone or in combination with of PRRSV-1.
    Madapong A; Saeng-Chuto K; Chaikhumwang P; Tantituvanont A; Saardrak K; Pedrazuela Sanz R; Miranda Alvarez J; Nilubol D
    Vet Microbiol; 2020 May; 244():108655. PubMed ID: 32402335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs.
    Kim T; Park C; Choi K; Jeong J; Kang I; Park SJ; Chae C
    Clin Vaccine Immunol; 2015 Jun; 22(6):631-40. PubMed ID: 25855554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy of a new modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous PRRSV challenge.
    Park C; Seo HW; Han K; Kang I; Chae C
    Vet Microbiol; 2014 Aug; 172(3-4):432-42. PubMed ID: 24970363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Fostera® PRRS modified live virus (MLV) vaccination strategy against a Thai highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) infection.
    Charoenchanikran P; Kedkovid R; Sirisereewan C; Woonwong Y; Arunorat J; Sitthichareonchai P; Sopipan N; Jittimanee S; Kesdangsakonwut S; Thanawongnuwech R
    Trop Anim Health Prod; 2016 Oct; 48(7):1351-9. PubMed ID: 27315207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a type 2 PRRSV modified live vaccine (PrimePac™ PRRS) against a Thai HP-PRRSV challenge.
    Sirisereewan C; Woonwong Y; Arunorat J; Kedkovid R; Nedumpun T; Kesdangsakonwut S; Suradhat S; Thanawongnuwech R; Teankum K
    Trop Anim Health Prod; 2018 Oct; 50(7):1509-1518. PubMed ID: 29696456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A porcine reproductive and respiratory syndrome virus candidate vaccine based on the synthetic attenuated virus engineering approach is attenuated and effective in protecting against homologous virus challenge.
    Evenson D; Gerber PF; Xiao CT; Halbur PG; Wang C; Tian D; Ni YY; Meng XJ; Opriessnig T
    Vaccine; 2016 Nov; 34(46):5546-5553. PubMed ID: 27742217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs.
    Park C; Choi K; Jeong J; Chae C
    Vet Microbiol; 2015 May; 177(1-2):87-94. PubMed ID: 25769646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the safety and efficacy of an attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus.
    Yu X; Zhou Z; Cao Z; Wu J; Zhang Z; Xu B; Wang C; Hu D; Deng X; Han W; Gu X; Zhang S; Li X; Wang B; Zhai X; Tian K
    Clin Vaccine Immunol; 2015 May; 22(5):493-502. PubMed ID: 25739919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an attenuated European subtype 1 porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs upon challenge with the East European subtype 3 PRRSV strain Lena.
    Trus I; Bonckaert C; van der Meulen K; Nauwynck HJ
    Vaccine; 2014 May; 32(25):2995-3003. PubMed ID: 24709589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of simultaneous vaccination with two modified live virus vaccines against porcine reproductive and respiratory syndrome virus types 1 and 2 in pigs.
    Kristensen CS; Kvisgaard LK; Pawlowski M; Holmgaard Carlsen S; Hjulsager CK; Heegaard PMH; Bøtner A; Stadejek T; Haugegaard S; Larsen LE
    Vaccine; 2018 Jan; 36(2):227-236. PubMed ID: 29191738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive immunomodulatory effects of heterologous DNA vaccine- modified live vaccine, prime-boost immunization, against the highly-pathogenic PRRSV infection.
    Sirisereewan C; Nedumpun T; Kesdangsakonwut S; Woonwong Y; Kedkovid R; Arunorat J; Thanawongnuwech R; Suradhat S
    Vet Immunol Immunopathol; 2017 Jan; 183():7-15. PubMed ID: 28063479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs.
    Fontanella E; Ma Z; Zhang Y; de Castro AM; Shen H; Halbur PG; Opriessnig T
    Vaccine; 2017 Jan; 35(1):125-131. PubMed ID: 27876202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live porcine reproductive and respiratory syndrome virus vaccines: Current status and future direction.
    Renukaradhya GJ; Meng XJ; Calvert JG; Roof M; Lager KM
    Vaccine; 2015 Aug; 33(33):4069-80. PubMed ID: 26148878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and biological characterization of a Porcine Reproductive and Respiratory Syndrome Virus 2 (PRRSV-2) causing significant clinical disease in the field.
    Kvisgaard LK; Larsen LE; Hjulsager CK; Bøtner A; Rathkjen PH; Heegaard PMH; Bisgaard NP; Nielsen J; Hansen MS
    Vet Microbiol; 2017 Nov; 211():74-83. PubMed ID: 29102125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.